228 related articles for article (PubMed ID: 33616828)
1. Voriconazole Versus Amphotericin B as Induction Therapy for Talaromycosis in HIV/AIDS Patients: A Retrospective Study.
Huang W; Li T; Zhou C; Wei F; Cao C; Jiang J
Mycopathologia; 2021 May; 186(2):269-276. PubMed ID: 33616828
[TBL] [Abstract][Full Text] [Related]
2. A Trial of Itraconazole or Amphotericin B for HIV-Associated Talaromycosis.
Le T; Kinh NV; Cuc NTK; Tung NLN; Lam NT; Thuy PTT; Cuong DD; Phuc PTH; Vinh VH; Hanh DTH; Tam VV; Thanh NT; Thuy TP; Hang NT; Long HB; Nhan HT; Wertheim HFL; Merson L; Shikuma C; Day JN; Chau NVV; Farrar J; Thwaites G; Wolbers M;
N Engl J Med; 2017 Jun; 376(24):2329-2340. PubMed ID: 28614691
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Voriconazole Versus Amphotericin B Deoxycholate Induction Treatment for HIV-Associated Talaromycosis: A Prospective Multicenter Cohort Study in China.
Zhou Y; Qin Y; Lu Y; Yuan J; Nie J; Liu M; Tian Q; Lan K; Zhou G; Qin Y; He K; Yu J; Jiang Z; Liu J; Liu S; Harypursat V; Chen Y
Infect Dis Ther; 2022 Aug; 11(4):1575-1590. PubMed ID: 35689792
[TBL] [Abstract][Full Text] [Related]
4. The delayed clearance of Talaromyces marneffei in blood culture may be associated with higher MIC of voriconazole after antifungal therapy among AIDS patients with talaromycosis.
Guo P; Chen W; Chen S; Chen M; Hu F; Chen X; Cai W; Tang X; Li L
PLoS Negl Trop Dis; 2023 Apr; 17(4):e0011201. PubMed ID: 37011093
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and Prognosis of Talaromyces marneffei Infection in Non-HIV-Infected Children in Southern China.
Guo J; Li BK; Li TM; Wei FL; Fu YJ; Zheng YQ; Pan KS; Huang CY; Cao CW
Mycopathologia; 2019 Dec; 184(6):735-745. PubMed ID: 31473910
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility profile of echinocandins, azoles and amphotericin B against yeast phase of Talaromyces marneffei isolated from HIV-infected patients in Guangdong, China.
Lei HL; Li LH; Chen WS; Song WN; He Y; Hu FY; Chen XJ; Cai WP; Tang XP
Eur J Clin Microbiol Infect Dis; 2018 Jun; 37(6):1099-1102. PubMed ID: 29536323
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and Prognosis of Talaromyces marneffei Infection in HIV-positive Children in Southern China.
Xue X; Zou J; Fang W; Liu X; Chen M; Arastehfar A; Ilkit M; Zheng Y; Qin J; Peng Z; Hu D; Liao W; Pan W
Mycopathologia; 2022 Jun; 187(2-3):169-180. PubMed ID: 35157189
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacodynamics of Amphotericin B Deoxycholate for Disseminated Infection Caused by
Le T; Ly VT; Thu NTM; Nguyen A; Thanh NT; Chau NVV; Thwaites G; Perfect J; Kolamunnage-Dona R; Hope W
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30420478
[TBL] [Abstract][Full Text] [Related]
9. Successful voriconazole treatment of Talaromyces marneffei infection in an HIV-negative patient with osteolytic lesions.
Ge Y; Xu Z; Hu Y; Huang M
J Infect Chemother; 2019 Mar; 25(3):204-207. PubMed ID: 30195473
[TBL] [Abstract][Full Text] [Related]
10. Administration of Voriconazole in Disseminated Talaromyces (Penicillium) Marneffei Infection: A Retrospective Study.
Ouyang Y; Cai S; Liang H; Cao C
Mycopathologia; 2017 Jun; 182(5-6):569-575. PubMed ID: 28108867
[TBL] [Abstract][Full Text] [Related]
11. Severe anemia, severe leukopenia, and severe thrombocytopenia of amphotericin B deoxycholate-based induction therapy in patients with HIV-associated talaromycosis: a subgroup analysis of a prospective multicenter cohort study.
Zhou Y; Lu T; Li Y; Qin Y; Lu Y; Tian Q; Lan K; Zhou G; Qin Y; Harypursat V; Li S; Lin S; Chen Y
BMC Infect Dis; 2023 Oct; 23(1):707. PubMed ID: 37864131
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei.
Stott KE; Le T; Nguyen T; Whalley S; Unsworth J; Ly VT; Kolamunnage-Dona R; Hope W
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0063621. PubMed ID: 34370587
[TBL] [Abstract][Full Text] [Related]
13. A case report of Talaromyces marneffei Oro-pharyngo-laryngitis: a rare manifestation of Talaromycosis.
Wongkamhla T; Chongtrakool P; Jitmuang A
BMC Infect Dis; 2019 Dec; 19(1):1034. PubMed ID: 31805893
[TBL] [Abstract][Full Text] [Related]
14. Prognosis and treatment effects of HIV-associated talaromycosis in a real-world patient cohort.
Klus J; Ly VT; Chan C; Le T
Med Mycol; 2021 Apr; 59(4):392-399. PubMed ID: 33644813
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics of tracheobronchial
Pan M; Fang G; Zheng F; Lin F; Zeng W; Qiu Y; Deng J; Chen X; Zhang J
Ann Med; 2023; 55(2):2276310. PubMed ID: 37967226
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of an abbreviated induction regimen of amphotericin B deoxycholate for cryptococcal meningoencephalitis: 3 days of therapy is equivalent to 14 days.
Livermore J; Howard SJ; Sharp AD; Goodwin J; Gregson L; Felton T; Schwartz JA; Walker C; Moser B; Müller W; Harrison TS; Perfect JR; Hope WW
mBio; 2014 Jan; 5(1):e00725-13. PubMed ID: 24473125
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and risk factors for readmission in HIV-infected patients with Talaromyces marneffei infection.
Shi M; Qin Y; Chen S; Wei W; Meng S; Chen X; Li J; Li Y; Chen R; Su J; Yuan Z; Wang G; Qin Y; Ye L; Liang H; Xie Z; Jiang J
PLoS Negl Trop Dis; 2023 Oct; 17(10):e0011622. PubMed ID: 37816066
[TBL] [Abstract][Full Text] [Related]
18. In Vitro Susceptibility of Berberine Combined with Antifungal Agents Against the Yeast Form of Talaromyces marneffei.
Luo H; Pan KS; Luo XL; Zheng DY; Andrianopoulos A; Wen LM; Zheng YQ; Guo J; Huang CY; Li XY; Hu R; Li YJ; Li TM; Joseph J; Cao CW; Liang G
Mycopathologia; 2019 Apr; 184(2):295-301. PubMed ID: 30805832
[TBL] [Abstract][Full Text] [Related]
19. [Clinical analysis of 7 children infected with
Xie G; Chen JH; Sun LF; Wang W; Li ZC; Wang WJ
Zhonghua Er Ke Za Zhi; 2022 Sep; 60(9):925-929. PubMed ID: 36038303
[No Abstract] [Full Text] [Related]
20. Efficacy of different antifungal drugs as initial treatment for patients with talaromycosis: A systematic review and meta-analysis.
Sheng L; Shen Q; Zhou J
J Mycol Med; 2021 Mar; 31(1):101108. PubMed ID: 33370708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
